Get the Stockscreener App
2.55
3.04%
-0.08
After Hours:
2.41
-0.14
-5.49%
Acumen Pharmaceuticals Inc stock is traded at $2.55, with a volume of 727.04K.
It is down -3.04% in the last 24 hours and down -9.89% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.63
Open:
$2.56
24h Volume:
727.04K
Relative Volume:
0.94
Market Cap:
$154.46M
Revenue:
-
Net Income/Loss:
$-133.35M
P/E Ratio:
-1.1555
EPS:
-2.2068
Net Cash Flow:
$-123.75M
1W Performance:
-12.67%
1M Performance:
-9.89%
6M Performance:
+79.58%
1Y Performance:
+119.83%
1-Day Range:
$2.3587
$2.75
1-Week Range:
$2.3587
$2.935
52-Week Range:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.55 | 159.31M | 0 | -133.35M | -123.75M | -2.2068 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
10.8M Acumen shares registered for resale (NASDAQ: ABOS) - Stock Titan
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ: ABOS) details sabirnetug Alzheimer’s program and funding risks - Stock Titan
Stifel reiterates Acumen Pharmaceuticals stock rating at buy - Investing.com
Acumen Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
ABOS: ALTITUDE-AD phase II and EBD advances drive robust pipeline and financial momentum - TradingView
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ABOS: ALTITUDE-AD trial advances, EBD pipeline expands, and $35.75M raised for Alzheimer's innovation - TradingView
Acumen Pharmaceuticals 2025 Financial Review - AlphaStreet
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements - Investing.com
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update - ChartMill
Patterns Watch: What is the earnings history of Acumen Pharmaceuticals IncSell Signal & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - Investing.com
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - Bitget
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Scheduled For March 26, 2026 - Benzinga
Acumen (NASDAQ: ABOS) deepens 2025 loss but extends cash runway toward key Alzheimer’s data - Stock Titan
BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -123.832 Million Vs. IBES Estimate USD -127.9 Million - TradingView
Acumen Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals, Inc. (Acumen Pharmaceuticals) recently officially released its annual financial report for the year ended December 31, 2025, and simultaneously reviewed the key business developments of the company over the past year. - Bitget
Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday - Defense World
ABOS (Acumen Pharmaceuticals) PB Ratio : 1.74 (As of Mar. 23, 2026) - GuruFocus
If You Invested $1,000 in Acumen Pharmaceuticals, Inc. (ABOS) - Stock Titan
Aug Rallies: What hedge funds are buying Acumen Pharmaceuticals IncWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acumen Pharmaceuticals Inc - GuruFocus
Dip Buying: How does Acumen Pharmaceuticals Inc perform in inflationary periods2026 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times
Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - MarketBeat
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
Acumen Pharmaceuticals at Stifel Forum: Strategic Insights on Alzheimer’s Drug - Investing.com Canada
ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView
Acumen Pharmaceuticals, Inc. unveils novel antibodies targeting amyloid beta oligomers at ADPD2026 - Traders Union
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Expected to Rise, BTIG Research Analyst Says - Defense World
Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Yahoo Finance
RA Capital boosts Acumen (ABOS) ownership to 29.5% after $20M PIPE buy - Stock Titan
Acumen Unveils Enhanced Brain Delivery Technology and Latest Alzheimer's Research Findings at International AD/PD Conference - citybiz
Private placement at Acumen to advance EBD program - BioWorld MedTech
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan
Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail
Dow Update: Whats Acumen Pharmaceuticals Incs historical return2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1 - Minichart
Institution Moves: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Acumen secures funding to advance enhanced brain delivery program - MSN
Acumen Pharmaceuticals, Inc. announced that it has received $35.749992 million in funding from RA Capital Management, L.P., ADAR1 Capital Management, LLC, Sands Capital Alternatives, LLC and other investors - marketscreener.com
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):